[HTML][HTML] A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer
Background ASP8273, a novel, small molecule, irreversible tyrosine kinase inhibitor (TKI)
specifically inhibits the epidermal growth factor receptor (EGFR) in patients with activating …
specifically inhibits the epidermal growth factor receptor (EGFR) in patients with activating …
[HTML][HTML] XL647—a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding …
MC Pietanza, TJ Lynch Jr, PN Lara Jr, J Cho… - Journal of thoracic …, 2012 - Elsevier
Introduction Although patients with non-small cell lung cancer (NSCLC) whose tumors
harbor epidermal growth factor receptor (EGFR) activating mutations commonly experience …
harbor epidermal growth factor receptor (EGFR) activating mutations commonly experience …
Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry
X Lu, L Yu, Z Zhang, X Ren, JB Smaill… - Medicinal research …, 2018 - Wiley Online Library
Both the first‐generation reversible epidermal growth factor receptor (EGFR) inhibitors
gefitinib and erlotinib and the second‐generation covalent epidermal growth factor receptor …
gefitinib and erlotinib and the second‐generation covalent epidermal growth factor receptor …
A phase I, dose escalation study of oral ASP8273 in patients with non–small cell lung cancers with epidermal growth factor receptor mutations
Abstract Purpose: Acquired EGFR T790M mutations are the most frequently identified
resistance mechanism to EGFR tyrosine kinase inhibitors (TKI) in patients with EGFR-mutant …
resistance mechanism to EGFR tyrosine kinase inhibitors (TKI) in patients with EGFR-mutant …
[HTML][HTML] Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2
PJ Hesketh, K Chansky, AJ Wozniak, FR Hirsch… - Journal of Thoracic …, 2008 - Elsevier
Purpose This phase II study (S0341) evaluated the efficacy and tolerability of single-agent
erlotinib in unselected chemotherapy-naive patients with advanced non-small cell lung …
erlotinib in unselected chemotherapy-naive patients with advanced non-small cell lung …
P1. 01-62 The third generation irreversible EGFR inhibitor HS-10296 in advanced non-small cell lung cancer patients
S Lu, R Camidge, C Yang, J Zhou, R Guo, C Chiu… - Journal of Thoracic …, 2018 - jto.org
Background The epidermal growth factor receptor (EGFR) T790M mutation is the most
common mechanism of drug resistance to EGFR tyrosine kinase inhibitors (TKIs) in non …
common mechanism of drug resistance to EGFR tyrosine kinase inhibitors (TKIs) in non …
[HTML][HTML] Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer
K Asami, S Atagi - World journal of clinical oncology, 2014 - ncbi.nlm.nih.gov
First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs),
including gefitinib and erlotinib, have proven to be highly effective agents for advanced non …
including gefitinib and erlotinib, have proven to be highly effective agents for advanced non …
ASP8273 selectively inhibits mutant EGFR signal pathway and induces tumor shrinkage in EGFR mutated tumor models
S Konagai, H Sakagami, H Yamamoto, H Tanaka… - Cancer Research, 2015 - AACR
Activating mutations of epidermal growth factor receptor (EGFR) are associated with the high
sensitivity of non-small cell lung cancer (NSCLC) patients to EGFR tyrosine kinase inhibitors …
sensitivity of non-small cell lung cancer (NSCLC) patients to EGFR tyrosine kinase inhibitors …
ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor‐naïve Japanese patients with EGFR mutation‐positive non‐small‐cell lung cancer
K Azuma, M Nishio, H Hayashi, K Kiura… - Cancer …, 2018 - Wiley Online Library
Epidermal growth factor receptor (EGFR) activating mutations occur in approximately 50% of
East Asian patients with non‐small‐cell lung cancer (NSCLC) and confer sensitivity to …
East Asian patients with non‐small‐cell lung cancer (NSCLC) and confer sensitivity to …
Clinical activity of ASP 8273 in Asian patients with non‐small‐cell lung cancer with EGFR activating and T790M mutations
H Murakami, H Nokihara, H Hayashi, T Seto… - Cancer …, 2018 - Wiley Online Library
Epidermal growth factor receptor (EGFR)‐activating mutations confer sensitivity to tyrosine
kinase inhibitor (TKI) treatment for non‐small‐cell lung cancer (NSCLC). ASP 8273 is a …
kinase inhibitor (TKI) treatment for non‐small‐cell lung cancer (NSCLC). ASP 8273 is a …